000			03814nam a22003855i 4500
001			289343
003			MX-SnUAN
005			20170705134219.0
007			cr nn 008mamaa
008			150903s2006 xxu| o |||| 0|eng d
020			_a9781592599622 _99781592599622
024	7		_a10.1385/1592599621 _2doi
035			_avtls000342889
039		9	_a201509030352 _bVLOAD _c201405070520 _dVLOAD _y201402061142 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aQH345
100	1		_aFabbro, Doriano. _eeditor. _9319529
245	1	0	_aProtein Tyrosine Kinases : _bFrom Inhibitors to Useful Drugs / _cedited by Doriano Fabbro, Frank McCormick.
264		1	_aTotowa, NJ : _bHumana Press, _c2006.
300			_brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aCancer Drug Discovery and Development
500			_aSpringer eBooks
505	0		_aProtein Tyrosine Kinases as Targets for Cancer and Other Indications -- Inhibitors of Signaling Interfaces -- PI3-Kinase Inhibition -- Src as a Target for Pharmaceutical Intervention -- Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target In Leukemia -- JAK Kinases in Leukemias, Lymphomas, and Multiple Myeloma -- Glivec® (Gleevec®, Imatinib, STI571) -- Platelet-Derived Growth Factor -- Structural Biology of Protein Tyrosine Kinases -- Testing of Signal Transduction Inhibitors in Animal Models of Cancer -- Phosphoproteomics in Drug Discovery and Development.
520			_aProtein kinases function as components of signal transduction pathways, playing a central role in the control of cell growth, metabolism, differentiation, and apoptosis. The development of selective protein tyrosine kinase (PTK) inhibitors that can block or modulate diseases, such as cancer, with abnormalities in these signaling pathways is considered a promising approach for drug development. Currently, more than 20 different PTKs are being considered as potential therapeutic targets in oncology. In Protein Tyrosine Kinases: From Inhibitors to Useful Drugs, leading researchers from the Novartis group that pioneered Gleevec/Glivec™ and from around the world comprehensively survey the state-of-the-art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made toward generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing PTK inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors. Authoritative and state-of-the-art, Protein Tyrosine Kinases: From Inhibitors to Useful Drugs details the key stages in the design of PTK inhibitors and their development into useful drugs.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aMcCormick, Frank. _eeditor. _9319530
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9781588293848
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1385/1592599621 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c289343 _d289343